Scodari Joseph C 4

What Happened Joseph C. Scodari, a director of Acurx Pharmaceuticals, was granted a stock option award covering 2,150 shares on April 20, 2026. The Form 4 reports the acquisition as a derivative award (price shown $0.00 for the grant) — this is a grant of options, not a purchase of common stock or an exercise. The award has a vesting condition and no immediate cash transaction or sale occurred.

Key Details

• Transaction date: April 20, 2026; reported on Form 4 filed April 22, 2026 (timely filing).
• Reported amount: 2,150 shares (stock option award); grant value reported as $0.00 on the Form 4 (reflects award, not cash purchase).
• Vesting: Per the filing footnote, the options vest on April 20, 2027 under the Issuer’s Director Compensation Policy.
• Shares owned after transaction: Not specified in this filing.
• Footnote: Award relates to service as a board director; no 10b5-1 plan or tax-withholding detail provided.

Context This is an equity compensation grant to a non-employee director that vests over one year. As a derivative award, it does not immediately increase free-float shares and is not an exercise or sale that signals a director liquidating or buying shares. Retail investors should note the grant as routine director compensation rather than an open-market purchase.